Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Teva settle UK Lipitor patent case

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor in the UK

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor (atorvastatin) in the UK.

Under the terms of the agreement Teva and the other settling parties have agreed not to sell the generic atorvastatin product in the UK before patent expiry in May 2012.

Teva said it acknowledged that Pfizer's Lipitor patent was valid and its product infringed Pfizer's rights.

Pfizer extended the drug's patent protection by six months to May 2012 in Europe, with the announcement of new paediatric data enabling the launch of a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

However, generic versions of the drug are already available in certain countries including Spain, Brazil and Mexico, with Lipitor's second quarter sales down from $2.81bn in 2010 to $2.59bn in 2011.

10th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics